A four-step synthesis of the indanone core of belzutifan (MK-6482) is described. This route starts from the commodity raw material dihydrocoumarin and was successfully demonstrated on a large scale to produce indanone 11 in the synthesis of belzutifan, an FDA-approved first-in-class therapy for the treatment of patients with certain types of Von Hippel–Lindau disease-associated tumors.
描述了 belzutifan (MK-6482) 茚满酮核心的四步合成。该路线从商品原料二氢香豆素开始,并成功大规模生产茚满酮11,用于合成 belzutifan,这是一种 FDA 批准的一流疗法,用于治疗某些类型的 Von Hippel-Lindau 患者疾病相关的肿瘤。